InVitria supplies animal component‑free recombinant proteins and cell culture supplements for the biopharmaceutical industry. The company develops and manufactures recombinant human serum albumin (rHSA) and other proteins produced in non‑mammalian systems to support cell culture, bioprocessing, and formulation.
Its products are designed to replace serum‑derived components, reducing variability and contamination risk while improving consistency and scalability. InVitria’s portfolio is used in media development, vaccine and biologics manufacturing, and emerging cell and gene therapy applications.
Ready-to-use CHO‑K1 transient expression kit simplifies lab workflows and speeds consistent protein production for early-stage biologics research.
The partnership enhances access to animal-free albumin, improving process efficiency and product stability in biopharma, supporting innovation in therapies and bioprocessing.
